BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: German N, Decker AM, Gilmour BP, Gay EA, Wiley JL, Thomas BF, Zhang Y. Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). J Med Chem 2014;57:7758-69. [PMID: 25162172 DOI: 10.1021/jm501042u] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Yang C, Zhang F, Deng G, Gong H. Amination of Aromatic Halides and Exploration of the Reactivity Sequence of Aromatic Halides. J Org Chem 2019;84:181-90. [DOI: 10.1021/acs.joc.8b02588] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
2 Gay EA, Guan D, Van Voorhies K, Vasukuttan V, Mathews KM, Besheer J, Jin C. Discovery and Characterization of the First Nonpeptide Antagonists for the Relaxin-3/RXFP3 System. J Med Chem 2022. [PMID: 35594150 DOI: 10.1021/acs.jmedchem.2c00508] [Reference Citation Analysis]
3 Gado F, Meini S, Bertini S, Digiacomo M, Macchia M, Manera C. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery. Future Med Chem 2019;11:2019-37. [PMID: 31517528 DOI: 10.4155/fmc-2019-0005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
4 Kulkarni PM, Kulkarni AR, Korde A, Tichkule RB, Laprairie RB, Denovan-Wright EM, Zhou H, Janero DR, Zvonok N, Makriyannis A, Cascio MG, Pertwee RG, Thakur GA. Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). J Med Chem 2016;59:44-60. [PMID: 26529344 DOI: 10.1021/acs.jmedchem.5b01303] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
5 Janero DR, Thakur GA. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target. Expert Opinion on Drug Discovery 2016;11:1223-37. [DOI: 10.1080/17460441.2016.1245289] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
6 Kulkarni AR, Garai S, Thakur GA. Scalable, One-Pot, Microwave-Accelerated Tandem Synthesis of Unsymmetrical Urea Derivatives. J Org Chem 2017;82:992-9. [PMID: 27966953 DOI: 10.1021/acs.joc.6b02521] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
7 Alaverdashvili M, Laprairie RB. The future of type 1 cannabinoid receptor allosteric ligands. Drug Metab Rev 2018;50:14-25. [PMID: 29355038 DOI: 10.1080/03602532.2018.1428341] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
8 Nguyen T, Gamage TF, Finlay DB, Decker AM, Langston TL, Barrus D, Glass M, Li JX, Kenakin TP, Zhang Y. Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior. J Med Chem 2021. [PMID: 34929081 DOI: 10.1021/acs.jmedchem.1c01432] [Reference Citation Analysis]
9 Banister SD, Krishna Kumar K, Kumar V, Kobilka BK, Malhotra SV. Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain. Medchemcomm 2019;10:647-59. [PMID: 31191856 DOI: 10.1039/c8md00595h] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 3.7] [Reference Citation Analysis]
10 Kulkarni AR, Garai S, Janero DR, Thakur GA. Design and Synthesis of Cannabinoid 1 Receptor (CB1R) Allosteric Modulators: Drug Discovery Applications. Methods Enzymol 2017;593:281-315. [PMID: 28750808 DOI: 10.1016/bs.mie.2017.06.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
11 Khurana L, Fu BQ, Duddupudi AL, Liao YH, Immadi SS, Kendall DA, Lu D. Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB1. J Med Chem 2017;60:1089-104. [PMID: 28059509 DOI: 10.1021/acs.jmedchem.6b01448] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
12 Hou L, Rong J, Haider A, Ogasawara D, Varlow C, Schafroth MA, Mu L, Gan J, Xu H, Fowler CJ, Zhang MR, Vasdev N, Ametamey S, Cravatt BF, Wang L, Liang SH. Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development. J Med Chem 2021;64:123-49. [PMID: 33379862 DOI: 10.1021/acs.jmedchem.0c01459] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Nguyen T, Li JX, Thomas BF, Wiley JL, Kenakin TP, Zhang Y. Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. Med Res Rev 2017;37:441-74. [PMID: 27879006 DOI: 10.1002/med.21418] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
14 Manning JJ, Green HM, Glass M, Finlay DB. Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias. Neuropharmacology 2021;193:108611. [PMID: 34000272 DOI: 10.1016/j.neuropharm.2021.108611] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Khurana L, Mackie K, Piomelli D, Kendall DA. Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. Neuropharmacology 2017;124:3-12. [PMID: 28527758 DOI: 10.1016/j.neuropharm.2017.05.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 9.4] [Reference Citation Analysis]
16 Scott CE, Kendall DA. Assessing Allosteric Modulation of CB1 at the Receptor and Cellular Levels. Methods Enzymol 2017;593:317-42. [PMID: 28750809 DOI: 10.1016/bs.mie.2017.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
17 Nguyen T, Gamage TF, Decker AM, Barrus D, Langston TL, Li JX, Thomas BF, Zhang Y. Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators. J Med Chem 2019;62:9806-23. [PMID: 31596583 DOI: 10.1021/acs.jmedchem.9b01161] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
18 Bertini S, Chicca A, Gado F, Arena C, Nieri D, Digiacomo M, Saccomanni G, Zhao P, Abood ME, Macchia M, Gertsch J, Manera C. Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor. Bioorg Med Chem 2017;25:6427-34. [PMID: 29079014 DOI: 10.1016/j.bmc.2017.10.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
19 Nguyen T, Decker AM, Langston TL, Mathews KM, Siemian JN, Li JX, Harris DL, Runyon SP, Zhang Y. Discovery of Novel Proline-Based Neuropeptide FF Receptor Antagonists. ACS Chem Neurosci 2017;8:2290-308. [PMID: 28737888 DOI: 10.1021/acschemneuro.7b00219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
20 Yamasaki T, Fujinaga M, Shimoda Y, Mori W, Zhang Y, Wakizaka H, Ogawa M, Zhang MR. Radiosynthesis and evaluation of new PET ligands for peripheral cannabinoid receptor type 1 imaging. Bioorg Med Chem Lett 2017;27:4114-7. [PMID: 28757061 DOI: 10.1016/j.bmcl.2017.07.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
21 Al-Zoubi R, Morales P, Reggio PH. Structural Insights into CB1 Receptor Biased Signaling. Int J Mol Sci 2019;20:E1837. [PMID: 31013934 DOI: 10.3390/ijms20081837] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
22 Nguyen T, Gamage TF, Decker AM, German N, Langston TL, Farquhar CE, Kenakin TP, Wiley JL, Thomas BF, Zhang Y. Diarylureas Containing 5-Membered Heterocycles as CB1 Receptor Allosteric Modulators: Design, Synthesis, and Pharmacological Evaluation. ACS Chem Neurosci 2019;10:518-27. [PMID: 30188693 DOI: 10.1021/acschemneuro.8b00396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
23 Kyeong M, Park Y, Gu A, Kim H, Hong S. Small molecule semiconductors for organic photovoltaics: a truncation approach. Synthetic Metals 2018;245:10-7. [DOI: 10.1016/j.synthmet.2018.08.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Hernandez-folgado L, Stevenson LA, Morales P, Gómez-cañas M, Pazos MR, Cascio MG, Jagerovic N, Elguero J, Pertwee R, Goya P. Exploring the Benzimidazole Ring as a Substitution for Indole in Cannabinoid Allosteric Modulators. Cannabis and Cannabinoid Research 2016;1:196-201. [DOI: 10.1089/can.2016.0003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Morales P, Goya P, Jagerovic N, Hernandez-Folgado L. Allosteric Modulators of the CB1 Cannabinoid Receptor: A Structural Update Review. Cannabis Cannabinoid Res 2016;1:22-30. [PMID: 28861476 DOI: 10.1089/can.2015.0005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
26 Nguyen T, German N, Decker AM, Li JX, Wiley JL, Thomas BF, Kenakin TP, Zhang Y. Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators. Bioorg Med Chem 2015;23:2195-203. [PMID: 25797163 DOI: 10.1016/j.bmc.2015.02.058] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
27 Nguyen T, Gamage TF, Decker AM, Finlay DB, Langston TL, Barrus D, Glass M, Harris DL, Zhang Y. Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids. Bioorg Med Chem 2021;41:116215. [PMID: 34015703 DOI: 10.1016/j.bmc.2021.116215] [Reference Citation Analysis]
28 Jagla CAD, Scott CE, Tang Y, Qiao C, Mateo-Semidey GE, Yudowski GA, Lu D, Kendall DA. Pyrimidinyl Biphenylureas Act as Allosteric Modulators to Activate Cannabinoid Receptor 1 and Initiate β-Arrestin-Dependent Responses. Mol Pharmacol 2019;95:1-10. [PMID: 30322873 DOI: 10.1124/mol.118.112854] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
29 Hernández-vázquez E, Salgado-barrera S, Ramírez-espinosa JJ, Estrada-soto S, Hernández-luis F. Synthesis and molecular docking of N′-arylidene-5-(4-chlorophenyl)-1-(3,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbohydrazides as novel hypoglycemic and antioxidant dual agents. Bioorganic & Medicinal Chemistry 2016;24:2298-306. [DOI: 10.1016/j.bmc.2016.04.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
30 Nguyen T, German N, Decker AM, Langston TL, Gamage TF, Farquhar CE, Li JX, Wiley JL, Thomas BF, Zhang Y. Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution. J Med Chem 2017;60:7410-24. [PMID: 28792219 DOI: 10.1021/acs.jmedchem.7b00707] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
31 Wang C, Du J, Zhang J, Tang K, Gao T, Xu Y, Sun L. Regioselective bromination of aryl ureas with Phenyliodine(III) diacetate and potassium bromide. Tetrahedron 2019;75:130621. [DOI: 10.1016/j.tet.2019.130621] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Lu D, Immadi SS, Wu Z, Kendall DA. Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor. Acta Pharmacol Sin 2019;40:324-35. [PMID: 30333554 DOI: 10.1038/s41401-018-0164-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
33 Mielnik CA, Lam VM, Ross RA. CB1 allosteric modulators and their therapeutic potential in CNS disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2021;106:110163. [DOI: 10.1016/j.pnpbp.2020.110163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
34 Thomas BF. Interactions of Cannabinoids With Biochemical Substrates. Subst Abuse 2017;11:1178221817711418. [PMID: 28607542 DOI: 10.1177/1178221817711418] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
35 Dopart R, Immadi SS, Lu D, Kendall DA. Structural Optimization of the Diarylurea PSNCBAM-1, an Allosteric Modulator of Cannabinoid Receptor 1. Curr Ther Res Clin Exp 2020;92:100574. [PMID: 32021660 DOI: 10.1016/j.curtheres.2019.100574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Nguyen T, Thomas BF, Zhang Y. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development. Curr Top Med Chem 2019;19:1418-35. [PMID: 31284863 DOI: 10.2174/1568026619666190708164841] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
37 Hryhorowicz S, Kaczmarek-Ryś M, Andrzejewska A, Staszak K, Hryhorowicz M, Korcz A, Słomski R. Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities. Int J Mol Sci 2019;20:E5874. [PMID: 31771126 DOI: 10.3390/ijms20235874] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
38 Hashimoto T, Ishii S, Yano R, Miura H, Sakata K, Takeuchi R. Iridium-Catalyzed [2+2+2] Cycloaddition of α,ω-Diynes with Cyanamides. Adv Synth Catal 2015;357:3901-16. [DOI: 10.1002/adsc.201500637] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
39 Gamage TF, Farquhar CE, Lefever TW, Thomas BF, Nguyen T, Zhang Y, Wiley JL. The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators. Neuropharmacology 2017;125:365-75. [PMID: 28803965 DOI: 10.1016/j.neuropharm.2017.08.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
40 Dopart R, Lu D, Lichtman AH, Kendall DA. Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity. Drug Metab Rev 2018;50:3-13. [PMID: 29355030 DOI: 10.1080/03602532.2018.1428342] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]